Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gefitinib + osimertinib
- Development stage
- Phase 2
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of two EGFR tyrosine kinase inhibitors (TKIs) used to treat EGFR-mutant non-small cell lung cancer (NSCLC). Gefitinib is a first-generation EGFR TKI while osimertinib is a third-generation EGFR TKI that specifically targets the T790M resistance mutation. This combination is designed as a preemptive strategy to delay or prevent the emergence of resistance mechanisms, particularly in cases where T790M and C797S mutations occur in trans. The combination has shown promising response rates in clinical trials with manageable toxicity profiles.
02
Targets
EGFR C797S (Epidermal Growth Factor Receptor C797S)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on gefitinib + osimertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gefitinib + osimertinib.